Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer metabolism therapeutics - Agios/Celgene

Drug Profile

Research programme: cancer metabolism therapeutics - Agios/Celgene

Alternative Names: AGI-14100; Glutaminase - Agios/Celgene; isocitrate dehydrogenase inhibitors - Agios/Celgene

Latest Information Update: 20 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Glutamine inhibitors; Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors; Phosphofructokinase modulators; Pyruvate kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Brain cancer; Cancer; Myelodysplastic syndromes

Most Recent Events

  • 14 Feb 2018 Agios Pharmaceuticals has issued patents and pending patents covering IDH mutant product candidates in countries worldwide
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top